GEES LINCTUS COUGH SYRUP DRIVERS COUGH LINCTUS

Dextromethorphan has a history of abuse in New Zealandand other countries.There are also other cough medicines available as pharmacy medicines which have been noted as atleast having a potential for abuse, for example cough medicines containing pholcodine and Geeslinctus which contains anhydrous morphine. Concern was raised over the easy availability of opioid (and opioid-like) coughmedicines which can be bought at a pharmacy or supermarket without healthcare professionalsupervision.Dextromethorphan is a substance that does not belong to the opioid family but has a chemicalstructure closely resembling the opioids. Suitable to recommend to patients.Proposal for reclassification of cough medicines containingdextromethorphan, opium tincture, squill oxymel andpholcodine to restricted medicinesPurposeMedsafe has recently been alerted to instances of abuse of cough medicines containingdextromethorphan. A discussion paper on the reclassification cited three cases between 20 of drug abuse or dependence on Robitussin by men aged 22, 31 and 34.Care Codeine Linctus reduces the urge to cough and so helps to soothe dry or irritating coughs. The affected brands of cough medicine include Gee's Linctus, Dimetapp, Coldrex, Codral, Benadryl, Robitussin, Panadol Cold and Flu Relief, Your Pharmacy, Strepsils for dry cough and some Vicks.

Gees Linctus Cough Syrup Drivers Cough Linctus

DXM toxicity occurs in a dose dependent fashion. NP Gees Linctus NP Hills Balsam Chesty Cough Liquid NP Hills Balsam Chesty Cough. NP Buttercup Syrups NP Cabdrivers Cough Linctus P Care+ Simple Linctus NP Covonia Catarrh Relief Formula NP Covonia Chesty Cough Mixture NP Covonia Cold & Flu Formula NP.

Some youngeradolescents consider DXM to be a harmless and legal high. Initially DXM wasintroduced as a tablet but when problems with misuse occurred, pharmaceutical companiesintroduced liquid formulations designed to reduce abuse by creating an unpleasant taste if ingestedin large amounts.DXM may encourage initiation and progression of substance abuse in teenagers. The effects of DXM is highly dependent on theindividual ability to metabolise DXM.DXM has a long history of abuse, especially among teenagers and young people. The different stages of effect are often referred to as'plateaus' by users, and are listed below along with the approximate range of doses associated withthem:Mild stimulation (first 'plateau'): adult dose: 100 to 200 mgEuphoria and hallucinations (second 'plateau'): adult dose: 200 to 400 mgDissociative 'out of body' state (third 'plateau'): adult dose: 300 to 600 mgComplete dissociation with unresponsiveness (fourth 'plateau'): adult dose: 600 mgThe typical strength of a cough tablet is 10-15 mg.

As a result, tolerance and physical and psychologicaldependence can develop rather quickly. On the other hand, a published studyfrom Scotland in 2016 showed that the trend was that more people abused codeine containingmedicines and less abused Gees linctus, see also section вЂњScientific informationвЂќ (3).Anhydrous morphine is highly addictive. Gees linctus has been reported to induce a вЂњlovely euphoria anddreaminessвЂќ, if a person is prepared to drink enough volume.

New Zealand classification to remainunchanged.30th meeting 26 November 2003Recommendation: over-the counter packs of dextromethorphan should be limited to packscontaining 600 milligrams or less and with recommended daily doses of not more than 120milligrams.The above recommendation was supported by a letter from Pfizer requesting reclassification fromprescription medicine to pharmacy-only medicine for sustained release liquid preparationscontaining 0.6% or less with a recommended dose not exceeding 60 milligrams. The recommendationswere that DXM should be classified as a: General Sale medicine when in liquid form containing 0.25% or less and when in solid doseform containing 15 milligrams or less per dose form Pharmacy-Only medicine when in liquid form containing more than 0.25% and not morethan 0.3% and when in solid dose form containing more than 15 milligrams and not morethan 30 milligrams per dose form Prescription medicine except when fulfilling the above criteria for sale as general sale orpharmacy-only medicines.27th meeting A recommendation by the Drugs and Poisons Scheduling Committee (NDPSC) in Australia, to changethe pharmacy-only entry to DXM in packs containing 600 mg or less of dextromethorphan in divided preparations containing 30 mg or less of dextromethorphan per dosage unit, witha recommended dose not exceeding 30 mg of dextromethorphan orIn undivided preparations containing 0.3 per cent or less of dextromethorphan, with arecommended dose not exceeding 30 mg of dextromethorphanwas rejected on the grounds that there was no evidence of abuse of general sale products in NewZealand.29th meeting The NDPSC opted not to adopt the MCC recommendation on dextromethorphan and to review theclassification in two years' time: No products available in Australia at general sale and a maximumpack size limit of 600 milligrams for all OTC products.